Please login to the form below

Not currently logged in
Email:
Password:

FDA clears Boehringer’s once-daily HIV pill

The US Food and Drug Administration has granted marketing approval for Boehringer Ingelheim's Viramune XR extended-release tablets, a one-pill, once-daily formulation of the HIV drug Viramune

The US Food and Drug Administration (FDA) has granted marketing approval for Boehringer Ingelheim's Viramune XR (nevirapine) extended-release tablets, a one-pill, once-daily formulation of the company's HIV drug Viramune, which was approved by the FDA in 1996 and is losing patent protection this year.

The extended-release formula has been cleared for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Boehringer is encouraging physicians to switch their patients to Viramune XR from the original version of the drug, an immediate-release pill that is taken twice daily and has now been approved by the FDA in much less expensive generic versions.

Boehringer said it has created a Viramune XR Co-Pay Savings Card to reduce the out-of-pocket cost of the new product to patients. The card, which is available to eligible patients for up to one year, will pay for the initial co-pay and up to $100 off each monthly prescription. The company noted that it has also expanded its Virology Patient Assistance programme to allow more patients to qualify to receive its medicines for free in the US.

The Viramune XR approval was based on a phase III study showing that the extended-release product achieved a virologic response that was as strong as the original formulation through 48 weeks and had a similar safety and tolerability profile. Both formulations were administered in the study in combination with Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate).

6th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...